Latest News
Enhertu recommended for EU approval in previously treated HER2 positive metastatic solid tumours
22 May 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Friday that Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unr...
OSE Immunotherapeutics reports positive Phase 2 ovarian cancer trial results
22 May 2026 - French biotechnology company OSE Immunotherapeutics SA (Euronext Paris:OSE) on Friday reported positive topline results from the Phase 2 TEDOVA trial evaluating Tedopi, with or without pembrolizumab, as maintenance therapy for platinum-...
INOVIO's oartner ApolloBio reports positive topline results from Phase 3 trial of VGX-3100
22 May 2026 - Biotechnology company INOVIO (NASDAQ:INO) announced on Thursday that its Chinese partner, ApolloBio, has reported positive topline results from its pivotal Phase 3 trial of VGX-3100, INOVIO's investigational DNA immunotherapy being...
Allergan Aesthetics reports positive CHMP opinion recommending approval of Boey (trenibotulinumtoxinE)
22 May 2026 - Allergan Aesthetics, an AbbVie company (NYSE:ABBV) focused on medical aesthetics, announced on Thursday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion...
Sobi reports positive topline results from Phase 3 study of pozdeutinurad in gout
22 May 2026 - Swedish biopharmaceutical company Sobi (STO:SOBI) on Thursday reported positive topline results from its pivotal Phase 3 REDUCE 2 study of pozdeutinurad (AR882) in adults with gout including those with uncontrolled gout (also referred t...